Table 3.
Tissue to blood ratios (T/B) and percentage of injected dose per gram of tissue corrected for decay (%ID/g) of the DU-145 (BLCA-38) and LNCaP-LN3 (J591) xenografts at the optimal days postadministration
| Antibody | Dose | Optimal days | T/B (mean ± SEM) | %ID/g (mean ± SEM) |
|---|---|---|---|---|
| BLCA-38 MAb | 100 μg | 5 | 0.70±0.05 | 7.21±0.30 |
| 8 | 0.88±0.05 | 3.12±0.40 | ||
| 200 μg | 5 | 1.12±0.40 | 8.11±3.97 | |
| 6 | 0.87±0.12 | 4.66±0.93 | ||
| BLCA-38 F(ab’)2 | 50 μg | 2 | 2.29±0.29 | 1.19±0.16 |
| 60 μg | 2 | 3.86±1.40 | 1.89±0.28 | |
| BLCA-38 F(ab’)2 | 100 μg | 2 | 2.37±0.27 | 1.09±0.08 |
| BLCA-38 Fab | 100 μg | 1 | 2.13±0.37 | 2.93±0.04 |
| J591 MAb | 100 μg | 9 | 1.09±0.26 | 4.41±1.45 |
| 200 μg | 7 | 1.05±0.21 | 4.91±1.37 | |
| 8 | 1.15±0.14 | 3.45±0.68 | ||
| J591 F(ab’)2 | 50 μg | 2 | 3.11±0.62 | 2.37±0.66 |
| 100 μg | 2 | 3.12±0.47 | 1.92±0.41 | |
| J591 Fab | 100 μg | 1 | 3.44±0.21 | 1.85±0.18 |